scholarly journals The impact of sphingosine kinase inhibitor-loaded nanoparticles on bioelectrical and biomechanical properties of cancer cells

Lab on a Chip ◽  
2016 ◽  
Vol 16 (1) ◽  
pp. 188-198 ◽  
Author(s):  
Hesam Babahosseini ◽  
Vaishnavi Srinivasaraghavan ◽  
Zongmin Zhao ◽  
Frank Gillam ◽  
Elizabeth Childress ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Cancer Cells ◽  
Microfluidic Chip ◽  
Kinase Inhibitor ◽  
Sphingosine Kinase ◽  
Biomechanical Properties ◽  
Free Drug ◽  
The Impact ◽  
Sphingosine Kinase Inhibitor

A microfluidic chip developed to study the effects of free-drug versus NPs-mediated drug delivery on cancer cells using their electromechanical biomarkers.

scholarly journals A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells

2009 ◽  
Vol 64 (5) ◽  
pp. 1053-1058 ◽  
Author(s):  
Meryem Bektas ◽  
Stewart P. Johnson ◽  
William E. Poe ◽  
Darell D. Bigner ◽  
Henry S. Friedman
Keyword(s):  
Cell Death ◽  
Kinase Inhibitor ◽  
Sphingosine Kinase ◽  
Glioblastoma Cells ◽  
Sphingosine Kinase Inhibitor

Abstract 1633: The sphingosine kinase inhibitor SKI-II blocks survival and MAPK signaling in human breast cancer in vitro

2010 ◽  
Author(s):  
Martin D. White ◽  
James W. Antoon ◽  
William D. Meacham ◽  
Evelyn M. Slaughter ◽  
Matthew E. Burow ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Kinase Inhibitor ◽  
Sphingosine Kinase ◽  
Mapk Signaling ◽  
Human Breast ◽  
Sphingosine Kinase Inhibitor

scholarly journals Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance

2019 ◽  
Vol 21 (1) ◽  
pp. 237 ◽  
Author(s):  
Husain Yar Khan ◽  
James Ge ◽  
Misako Nagasaka ◽  
Amro Aboukameel ◽  
Gabriel Mpilla ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Cancer Cells ◽  
Rho Gtpase ◽  
Kinase Inhibitor ◽  
Progression Free Survival ◽  
Anaplastic Thyroid Cancer ◽  
Therapy Resistance ◽  
Molecular Profile ◽  
The Impact ◽  
Thyroid Cancer Cells

Lenvatinib is a multitargeted tyrosine kinase inhibitor (TKI) that shows improved median progression-free survival (PFS) in patients with thyroid carcinomas. However, virtually all patients ultimately progress, indicating the need for a better understanding of the mechanisms of resistance. Here, we examined the molecular profile of anaplastic thyroid cancer cells (8505C) exposed to lenvatinib and found that long-term exposure to lenvatinib caused phenotypic changes. Consistent with change toward mesenchymal morphology, activation of pro-survival signaling, nuclear exporter protein exportin 1 (XPO1) and Rho GTPase effector p21 activated kinases (PAK) was also observed. RNA-seq analysis showed that prolonged lenvatinib treatment caused alterations in numerous cellular pathways and several oncogenes such as CEACAM (carcinoembryonic antigen-related cell adhesion molecule) and NUPR1 (Nuclear protein 1) were also upregulated. Further, we evaluated the impact of XPO1 and PAK4 inhibition in the presence or absence of lenvatinib. Targeted inhibition of XPO1 and PAK4 could sensitize the 8505C cells to lenvatinib. Both XPO1 and PAK4 inhibitors, when combined with lenvatinib, showed superior anti-tumor activity in 8505C sub-cutaneous xenograft. These studies bring forward novel drug combinations to complement lenvatinib for treating anaplastic thyroid cancer. Such combinations may possibly reduce the chances of lenvatinib resistance in thyroid cancer patients.

scholarly journals F-12509A, a New Sphingosine Kinase Inhibitor, Produced by a Discomycete.

2000 ◽  
Vol 53 (5) ◽  
pp. 459-466 ◽  
Author(s):  
KEITA KONO ◽  
MASAHIRO TANAKA ◽  
TAKESHI OGITA ◽  
TSUYOSHI HOSOYA ◽  
TAKAFUMI KOHAMA
Keyword(s):  
Kinase Inhibitor ◽  
Sphingosine Kinase ◽  
Sphingosine Kinase Inhibitor

scholarly journals Comparative analysis of the effects of a sphingosine kinase inhibitor to temozolomide and radiation treatment on glioblastoma cell lines

2017 ◽  
Vol 18 (6) ◽  
pp. 400-406 ◽  
Author(s):  
Liliana R. Oancea-Castillo ◽  
Carmen Klein ◽  
Amir Abdollahi ◽  
Klaus-Josef Weber ◽  
Anne Régnier-Vigouroux ◽  
...  
Keyword(s):  
Comparative Analysis ◽  
Cell Lines ◽  
Kinase Inhibitor ◽  
Radiation Treatment ◽  
Sphingosine Kinase ◽  
Glioblastoma Cell ◽  
Sphingosine Kinase Inhibitor ◽  
Glioblastoma Cell Lines

scholarly journals A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties

Oncotarget ◽  
2015 ◽  
Vol 6 (9) ◽  
pp. 7065-7083 ◽  
Author(s):  
Melissa R. Pitman ◽  
Jason A. Powell ◽  
Carl Coolen ◽  
Paul A.B. Moretti ◽  
Julia R. Zebol ◽  
...  
Keyword(s):  
Kinase Inhibitor ◽  
Sphingosine Kinase ◽  
Anti Cancer ◽  
Sphingosine Kinase Inhibitor

Abstract 2537: The novel sphingosine kinase inhibitor ABC294640 blocks survival and tumorigenesis in chemo- And endocrine resistant breast cancer

2010 ◽  
Author(s):  
James W. Antoon ◽  
Martin D. White ◽  
Matthew M. Gestaut ◽  
Evelyn M. Slaughter ◽  
Steven Elliott ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Kinase Inhibitor ◽  
Sphingosine Kinase ◽  
The Novel ◽  
Sphingosine Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document